Tag: serdexmethylphenidate
KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV...
KP879, KemPharm’s Lead Product Candidate Based on SDX and Intended for the Treatment of Stimulant Use Disorder (SUD), Could Be Schedule IV, If...
KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for...
Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3, at 8:30 a.m. ET CELEBRATION, Fla., March 02,...